Immunity to chronic myelogenous leukemia

Hematology/Oncology Clinics of North America

Volumn 18, Issue 3, 2004, Pages 733-752

  Kurbegov, Dax ^a   Molldrem, Jeffrey J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; RECOMBINANT ALPHA INTERFERON;

CANCER REGRESSION; CANCER SURVIVAL; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CLINICAL RESEARCH; DENDRITIC CELL; DRUG TARGETING; HLA MATCHING; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR IMMUNOLOGY;

ANTIBODY FORMATION; HUMANS; IMMUNITY; IMMUNITY, CELLULAR; IMMUNIZATION; LEUKEMIA, MYELOID, CHRONIC;

EID: 3242764528     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2004.03.007     Document Type: Review

References (112)

1. Kaklamanis L., Gatter K.C., Hill A.B., Mortensen N., Harris A.L., Krausa P., et al. Loss of HLA class-I alleles, heavy chains and beta 2-microglobulin in colorectal cancer. Int J Cancer. 51:1992;379-385
2. Kaklamanis L., Hill A. MHC loss in colorectal tumours: evidence for immunoselection? Cancer Surv. 13:1992;155-171
3. Restifo N.P., Esquivel F., Kawakami Y., Yewdell J.W., Mule J.J., Rosenberg S.A., et al. Identification of human cancers deficient in antigen processing. J Exp Med. 177:1993;265-272
4. Speiser D.E., Miranda R., Zakarian A., Bachmann M.F., McKall-Faienza K., Odermatt B., et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med. 186:1997;645-653
5. Staveley-O'Carroll K., Sotomayor E., Montgomery J., Borrello I., Hwang L., Fein S., et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA. 95:1998;1178-1183
6. Davis T.A., Hsu F.J., Caspar C.B., van Beckhoven A., Czerwinsk D.K., Liles T.M., et al. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma. Biol Blood Marrow Transplant. 7:2001;517-522
7. Liso A., Stockerl-Goldstein K.E., Auffermann-Gretzinger S., Benike C.J., Reichardt V., van Beckhoven A., et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 6:2000;621-627
8. Allan N.C., Richards S.M., Shepherd P.C. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet. 345:1995;1392-1397
9. Bonifazi F., de Vivo A., Rosti G., Guilhot F., Guilhot I., Trabacchi E., et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 98:2001;3074-3081
10. Kantarjian H.M., Smith T.L., O'Brien S., Beran M., Pierce S., Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med. 122:1995;254-261
11. Ozer H., George S., Schiffer C., Rao K., Rao P., Wurster-Hill D., et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583 [comments]. Blood. 82:1993;2975-2984
12. Talpaz M., Kantarjian H.M., McCredie K., Trujillo J.M., Keating M.J., Gutterman J.U. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 314:1986;1065-1069
13. 1) patients [abstract]. Blood. 92:1998;317a
14. Delforge A., Vandenplas B., Lagneaux L., Loos M., Bron D., Debusscher L., et al. Influence of recombinant alpha and gamma interferons on the in vitro proliferation of myeloid and leukemic progenitors. Eur J Haematol. 44:1990;307-311
15. Hofbauer G.F., Geertsen R., Laine E., Burg G., Dummer R. Impact of interferons on the expression of melanoma-associated antigens in melanoma short-term cell cultures. Melanoma Res. 11:2001;213-218
16. Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 75:1990;555-562
17. Sehn L.H., Alyea E.P., Weller E., Canning C., Lee S., Ritz J., et al. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol. 17:1999;561-568
18. Giralt S.A., Kolb H.J. Donor lymphocyte infusions. Curr Opin Oncol. 8:1996;96-102
19. Kolb H., Schattenberg A., Goldman J., Hertenstein B., Jacobsen N., Arcese W., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [comments]. Blood. 86:1995;2041-2050
20. Kolb H.J., Mittermuller J., Holler E., Thalmeier K., Bartram C.R. Graft-versus-host reaction spares normal stem cells in chronic myelogenous leukemia. Bone Marrow Transplant. 17:1996;449-452
21. van Rhee F., Lin F., Cullis J.O., Spencer A., Cross N.C., Chase A., et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood. 83:1994;3377-3383
22. Kolb H.J., Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol. 9:1997;139-145
23. Ribas A., Butterfield L.H., Glaspy J.A., Economou J.S. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 21:2003;2415-2432
24. Altman J.D., Moss P.A., Goulder P.J., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94-96
25. Molldrem J.J., Lee P.P., Wang C., Felio K., Kantarjian H.M., Champlin R.E., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 6:2000;1018-1023
26. Pardoll D.M. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol. 2:2002;227-238
27. Scott D.M., Ehrmann I.E., Ellis P.S., Bishop C.E., Agulnik A.I., Simpson E., et al. Identification of a mouse male-specific transplantation antigen H-Y. Nature. 376:1995;695-698
28. Shtivelman E., Lifshitz B., Gale R.P., Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 315:1985;550-554
29. Bocchia M., Wentworth P.A., Southwood S., Sidney J., McGraw K., Scheinberg D.A., et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood. 85:1995;2680-2684
30. Bocchia M., Korontsvit T., Xu Q., Mackinnon S., Yang S.Y., Sette A., et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 87:1996;3587-3592
31. Clark R.E., Christmas S.E. BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia. Leuk Lymphoma. 42:2001;871-880
32. Clark R.E., Dodi I.A., Hill S.C., Lill J.R., Aubert G., Macintyre A.R., et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood. 98:2001;2887-2893
33. Norbury L.C., Clark R.E., Christmas S.E. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br J Haematol. 109:2000;616-621
34. Yotnda P., Firat H., Garcia-Pons F., Garcia Z., Gourru G., Vernant J.-P., et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest. 101:1998;2290-2296
35. Wagner W.M., Ouyang Q., Pawelec G. Peptides spanning the fusion region of Abl/Bcr are immunogenic and sensitize CD8(+) T lymphocytes to recognize native chronic myelogenous leukemia. Leukemia. 16:2002;2341-2343
36. Muller-Berat N., Minowada J., Tsuji-Takayama K., Drexler H., Lanotte M., Wieslander J., et al. The phylogeny of proteinase 3/myeloblastin, the autoantigen in Wegener's granulomatosis, and myeloperoxidase as shown by immunohistochemical studies on human leukemic cell lines. Clin Immunol Immunopathol. 70:1994;51-59
37. Sturrock A.B., Franklin K.F., Rao G., Marshall B.C., Rebentisch M.B., Lemons R.S., et al. Structure, chromosomal assignment, and expression of the gene for proteinase-3. The Wegener's granulomatosis autoantigen. J Biol Chem. 267:1992;21193-21199
38. Bories D., Raynal M.C., Solomon D.H., Darzynkiewicz Z., Cayre Y.E. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell. 59:1989;959-968
39. Witko-Sarsat V., Canteloup S., Durant S., Desdouets C., Chabernaud R., Lemarchand P., et al. Cleavage of p21waf1 by proteinase-3, a myeloid-specific serine protease, potentiates cell proliferation. J Biol Chem. 277:2002;47338-47347
40. Dengler R., Munstermann U., al-Batran S., Hausner I., Faderl S., Nerl C., et al. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br J Haematol. 89:1995;250-257
41. Griffith M.E., Couhart A., Pusey C.D. T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Clin Exp Immunol. 103:1996;253-258
42. Ohlsson S., Wieslander J., Segelmark M. Increased circulating levels of proteinase 3 in patients with anti-neutrophilic cytoplasmic autoantibodies- associated systemic vasculitis in remission. Clin Exp Immunol. 131:2003;528-535
43. Sommarin Y., Rasmussen N., Wieslander J. Characterization of monoclonal antibodies to proteinase-3 and application in the study of epitopes for classical anti-neutrophil cytoplasm antibodies. Exp Nephrol. 3:1995;249-256
44. Molldrem J.J., Lee P.P., Wang C., Champlin R.E., Davis M.M. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59:1999;2675-2681
45. Rezvani K., Grube M., Brenchley J.M., Sconocchia G., Fujiwara H., Price D.A., et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 102:2003;2892-2900
46. Azuma T., Makita M., Ninomiya K., Fujita S., Harada M., Yasukawa M. Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Br J Haematol. 116:2002;601-603
47. Bellantuono I., Gao L., Parry S., Marley S., Dazzi F., Apperley J., et al. Two distinct HLA-A0201-presented epitopes of the Wilms' tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood. 100:2002;3835-3837
48. Scheibenbogen C., Letsch A., Thiel E., Schmittel A., Mailaender V., Baerwolf S., et al. CD8 T-cell responses to Wilms' tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 100:2002;2132-2137
49. den Haan J.M., Meadows L.M., Wang W., Pool J., Blokland E., Bishop T.L., et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science. 279:1998;1054-1057
50. Goulmy E., Schipper R., Pool J., Blokland E., Falkenburg J.H., Vossen J., et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 334:1996;281-285
51. Amrolia P.J., Reid S.D., Gao L., Schultheis B., Dotti G., Brenner M.K., et al. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood. 101:2003;1007-1014
52. Raptis A., Clave E., Mavroudis D., Molldrem J., Rhee F., Barrett A.J. Polymorphism in CD33 and CD34 genes: a source of minor histocompatibility antigens on haemopoietic progenitor cells? Br J Haematol. 102:1998;1354-1358
53. Jiang Y.Z., Barrett J. The allogeneic CD4+ T-cell-mediated graft-versus-leukemia effect. Leuk Lymphoma. 28:1997;33-42
54. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 333:1995;1038-1044
55. Gebe J.A., Falk B.A., Rock K.A., Kochik S.A., Heninger A.K., Reijonen H., et al. Low-avidity recognition by CD4+ T cells directed to self-antigens. Eur J Immunol. 33:2003;1409-1417
56. Farag S.S., Fehniger T.A., Ruggeri L., Velardi A., Caligiuri M.A. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood. 100:2002;1935-1947
57. Robertson M.J., Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 76:1990;2421-2438
58. Cooper M.A., Fehniger T.A., Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol. 22:2001;633-640
59. Colonna M., Dohring C., Samaridis J., Scheidegger D., Dessing M., Cella M., et al. Human killer inhibitory receptors: specificity for HLA-class I molecules and mechanisms of signal transduction. Transplant Proc. 28:1996;3035
60. Lotzova E., Herberman R.B. Reassessment of LAK phenomenology: a review. Nat Immun Cell Growth Regul. 6:1987;109-115
61. Lotzova E., Savary C.A., Herberman R.B. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol. 138:1987;2718-2727
62. Parham P., McQueen K.L. Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat Rev Immunol. 3:2003;108-122
63. Valiante N.M., Uhrberg M., Shilling H.G., Lienert-Weidenbach K., Arnett K.L., D'Andrea A., et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 7:1997;739-751
64. Dohring C., Scheidegger D., Samaridis J., Cella M., Colonna M. A human killer inhibitory receptor specific for HLA-A1.2. J Immunol. 156:1996;3098-3101
65. Wagtmann N., Rajagopalan S., Winter C.C., Peruzzi M., Long E.O. Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. Immunity. 3:1995;801-809
66. Ruggeri L., Capanni M., Casucci M., Volpi I., Tosti A., Perruccio K., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 94:1999;333-339
67. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 295:2002;2097-2100
68. Shlomchik W.D., Couzens M.S., Tang C.B., McNiff J., Robert M.E., Liu J., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 285:1999;412-415
69. Sawyers C.L. Medical progress: chronic myeloid leukemia. N Engl J Med. 340:1999;1330-1340
70. Baron F., Turhan A.G., Giron-Michel J., Azzarone B., Bentires-Alj M., Bours V., et al. Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood. 99:2002;2107-2113
71. Wu C.J., Yang X.-F., McLaughlin S., Neuberg D., Canning C., Stein B., et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 106:2000;705-714
72. Carey T.E., Takahashi T., Resnick L.A., Oettgen H.F., Old L.J. Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci USA. 73:1976;3278-3282
73. Sahin U., Tureci O., Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol. 9:1997;709-716
74. Yang X.-F., Wu C.J., McLaughlin S., Chillemi A., Wang K.S., Canning C., et al. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci USA. 98:2001;7492-7497
75. Jager E., Nagata Y., Gnjatic S., Wada H., Stockert E., Karbach J., et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA. 97:2000;4760-4765
76. Champlin R.E. T-cell depletion for bone marrow transplantation: effects on graft rejection, graft-versus-host disease, graft-versus-leukemia, and survival. Cancer Treat Res. 50:1990;99-111
77. Elmaagacli A.H., Peceny R., Steckel N., Trenschel R., Ottinger H., Grosse-Wilde H., et al. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood. 101:2003;446-453
78. Alyea E.P., Soiffer R.J., Canning C., Neuberg D., Schlossman R., Pickett C., et al. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 91:1998;3671-3680
79. Giralt S., Hester J., Huh Y., Hirsch-Ginsberg C., Rondon G., Seong D., et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 86:1995;4331-4343
80. Visani G., Gamberi B., Greenberg P., Advani R., Gulati S., Champlin R., et al. The use of GM-CSF as an adjunct to autologous/syngeneic bone marrow.transplantation: a prospective randomized controlled trial. Bone Marrow Transplant. 7(Suppl 2):1991;81
81. Shimoni A., Gajewski J.A., Donato M., Martin T., O'Brien S., Talpaz M., et al. Long-term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 7:2001;568-575
82. Falkenburg J.H., Wafelman A.R., Joosten P., Smit W.M., van Bergen C.A., Bongaerts R., et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood. 94:1999;1201-1208
83. Barthe C., Gharbi M.J., Lagarde V., Chollet C., Cony-Makhoul P., Reiffers J., et al. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to ST1571. Br J Haematol. 119:2002;109-111
84. Kreuzer K.A., Le Coutre P., Landt O., Na I.K., Schwarz M., Schultheis K., et al. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol. 82:2003;284-289
85. Sacha T., Hochhaus A., Hanfstein B., Muller M.C., Rudzki Z., Czopek J., et al. ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patients who progress to myeloid blast crisis. Leuk Res. 27:2003;1163-1166
86. Okamoto S., Watanabe R., Takahashi S., Mori T., Izeki T., Nagayama H., et al. Long-term follow-up of allogeneic bone marrow transplantation after reduced-intensity conditioning in patients with chronic myelogenous leukemia in the chronic phase. Int J Hematol. 75:2002;493-498
87. Or R., Shapira M.Y., Resnick I., Amar A., Ackerstein A., Samuel S., et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood. 101:2003;441-445
88. Italian Cooperative Study Group on Chronic Myeloid Leukemia Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 330:1994;820-825
89. Chronic Myeloid Leukemia Trialists' Collaborative Group Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst. 89:1997;1616-1620
90. Italian Cooperative Study Group on Chronic Myeloid Leukemia Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood. 92:1998;1541-1548
91. Hehlmann R., Heimpel H., Hasford J., Kolb H.J., Pralle H., Hossfeld D.K., et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 84:1994;4064-4077
92. Ohnishi K., Ohno R., Tomonaga M., Kamada N., Onozawa K., Kuramoto A., et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 86:1995;906-916
93. Molldrem J.J., Clave E., Jiang Y.Z., Mavroudis D., Raptis A., Hensel N., et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 90:1997;2529-2534
94. Molldrem J.J., Lee P.P., Kant S., Wieder E., Jiang W., Lu S., et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest. 111:2003;639-647
95. Theze J., Alzari P.M., Bertoglio J. Interleukin 2 and its receptors: recent advances and new immunological functions. Immunol Today. 17:1996;481-486
96. Adler A., Chervenick P.A., Whiteside T.L., Lotzova E., Herberman R.B. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood. 71:1988;709-716
97. Cortes J.E., Kantarjian H.M., O'Brien S., Giles F., Keating M.J., Freireich E.J., et al. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer. 85:1999;1506-1513
98. Charak B.S., Brynes R.K., Groshen S., Chen S.C., Mazumder A. Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood. 76:1990;2187-2190
99. Pan L., Ohnishi K., Zhang W.J., Yoshida H., Maksumova L., Muratkhodjaev F., et al. In vitro IL-12 treatment of peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes: increase in cytotoxicity and reduction in WT1 gene expression. Leukemia. 14:2000;1634-1641
100. Vitale A., Guarini A., Latagliata R., Cignetti A., Foa R. Cytotoxic effecters activated by low-dose IL-2 plus IL-12 lyse IL-2-resistant autologous acute myeloid leukaemia blasts. Br J Haematol. 101:1998;150-157
101. Pinilla J., Cathcart K., Korontsvit T., Schwartz J. A phase II trial of patients with CML using a multivalent BCR-ABL oncogene product fusion peptide vaccine. Proc Am Soc Clin Oncol. 22:2003;168
102. Takahashi T., Tanaka Y., Nieda M., Azuma T., Chiba S., Juji T., et al. Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk Res. 27:2003;795-802
103. Li Z., Qiao Y., Laska E., Kulko J. Combination of imatinib mesylate with autologous leukocyte derived heat shock protein 70 vaccine for chronic myelogenous leukemia [abstract 664]. Proc Am Soc Clin Oncol. 22:2003;166
104. Molldrem J., Kant S., Lu S., Rios R., Wieder E. Peptide vaccination with PR1 elicits active T cell immunity that induces cytogenetic remission in acute myelogenous leukemia. Presented at the American Society of Hematology Conference, Philadelphia, 2002
105. Bowman L., Grossmann M., Rill D., Brown M., Zhong W.Y., Alexander B., et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 92:1998;1941-1949
106. Dilloo D., Bacon K., Holden W., Zhong W., Burdach S., Zlotnik A., et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med. 2:1996;1090-1095
107. Borrello I., Sotomayor E.M., Rattis F.M., Cooke S.K., Gu L., Levitsky H.I. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood. 95:2000;3011-3019
108. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 90:1993;3539-3543
109. Borrello I., Sotomayor E.M., Cooke S., Levitsky H.I. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther. 10:1999;1983-1991
110. Heemskerk H., de Paus R., van den Muijsenberg J., Willemze R., Falkenburg J. Rescue of antigen specificity of non-proliferating T cells by TCRab gene transfer into unselected peripheral blood T cells [abstract 2125]. Am Soc Hematol. 2001
111. Roessig C., Scherer S.P., Baer A., Vormoor J., Rooney C.M., Brenner M.K., et al. Targeting CD19 with genetically modified EBV-specific human T lymphocytes. Ann Hematol. 81(Suppl 2):2002;S42-S43
112. Rossig C., Brenner M.K. Chimeric T-cell receptors for the targeting of cancer cells. Acta Haematol. 110:2003;154-159